Not all science news is about breakthroughs. Sometimes the most important findings are the ones that close doors, even doors we really wanted to walk through.
A phase 3 clinical trial published in The Lancet tested whether simvastatin, a common cholesterol-lowering drug that your grandparents might be taking, could slow disability progression in secondary progressive multiple sclerosis (SPMS). The drug had looked promising in earlier trials. It reduced brain atrophy by an impressive 43%. But in this larger, longer study of nearly 1,000 patients? It didn't work. Not a little bit. At all.
The Backstory: Why This Drug Seemed Like a Good Bet
Multiple sclerosis involves the immune system attacking the nervous system, but that's only part of the story. For relapsing MS, where the immune system periodically flares up, we've got drugs that can suppress those flares. Great progress has been made there.
But disability progression in MS is a different beast. It's driven by slow neurodegeneration, aging processes, and vascular factors that don't really respond to the immunotherapy playbook. Secondary progressive MS, in particular, has stubbornly resisted treatment attempts.
An earlier trial called MS-STAT (phase 2b) had found that simvastatin significantly reduced brain shrinkage in SPMS patients compared to placebo. Simvastatin has known anti-inflammatory effects. It might be neuroprotective. And here's the kicker: it's been used for decades to lower cholesterol, so we know it's safe. It's cheap. It's well-understood.
A cheap, safe, widely available drug for a disease with few options? Researchers were understandably excited.
What Actually Happened When They Tested It Properly
MS-STAT2 was the big test. The researchers randomized 964 participants with SPMS to either simvastatin (80mg) or placebo for up to 4.5 years. That's nearly a thousand people committing years of their lives to a clinical trial. That's a serious effort.
The primary outcome they were looking at was time to confirmed disability progression. Did people taking simvastatin stay more functional for longer?
The result: 36% of placebo patients progressed. 40% of simvastatin patients progressed. The drug showed no benefit. If anything, the trend was slightly in the wrong direction (though not statistically significant, so probably just noise).
This is about as clean a negative result as you can get. The earlier promising signal from the smaller trial didn't hold up when tested properly.
Failure Is Data Too
This is disappointing news for patients with SPMS, who have few good options. But publishing negative results like this is genuinely important for several reasons.
First, patients and doctors can make informed decisions. Before this trial, someone with SPMS might have reasonably wondered whether they should ask about simvastatin. Now they know: if you're taking it for your heart, great, but don't take it specifically hoping it will help your MS. That's useful information.
Second, research resources can go elsewhere. Clinical trials are expensive and require years of effort from researchers and patients alike. Closing this avenue decisively means the field can focus on more promising approaches instead of wondering whether simvastatin might still be worth pursuing.
Third, this tells us something about biomarkers. The earlier trial found reduced brain atrophy, which sounds like it should mean something. But brain atrophy didn't translate into preserved function. Maybe brain atrophy isn't the biomarker we should be focusing on. Maybe it correlates with some aspects of MS but not the ones that matter most to patients. That's a lesson that applies beyond just this one drug.
The Uncomfortable Reality of Progressive MS
Secondary progressive MS remains stubbornly difficult to treat. Unlike relapsing MS, where you can suppress immune flares, progressive MS involves slow neurodegeneration that current therapies barely touch.
This wasn't the first drug to fail against progressive MS, and it won't be the last. The biology of neurodegeneration is harder to reverse or slow than the biology of immune attacks. We don't yet have the tools to stop neurons from slowly dying once that process gets going.
But each negative result, properly conducted and properly published, helps narrow the search. We know more about what doesn't work, which is actually a step toward finding what does work. The researchers who ran MS-STAT2 did the field a service by testing this hypothesis rigorously and reporting the results honestly, even though the results were disappointing.
Sometimes science means spending years and millions of dollars to learn that your promising idea doesn't pan out. That's frustrating, but it's how knowledge actually advances. The path to effective treatments runs through a lot of dead ends, and the only way forward is to explore them, mark them as dead ends, and try the next path.
Reference: Chataway J, et al. (2025). Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. doi: 10.1016/S0140-6736(25)01039-6 | PMID: 41045938
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.